3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Hiroaki Mitsuya,Kent J. Weinhold,P A Furman,M H St Clair,S N Lehrman,Robert C. Gallo,Dani P. Bolognesi,David Walter Barry,Samuel Broder +8 more
Reads0
Chats0
TLDR
The antiviral effects of a thymidine analogue,3'-azido-3'-deoxythymidine (BW A509U), which, as a triphosphate, inhibits the reverse transcriptase of HTLV-III/LAV, and the in vitro immune functions of normal T cells remain basically intact.Abstract:
The acquired immune deficiency syndrome (AIDS) is thought to result from infection of T cells by a pathogenic human retrovirus, human T-lymphotropic virus type III (HTLV-III) or lymphadenopathy-associated virus (LAV). In this report, we describe the antiviral effects of a thymidine analogue,3'-azido-3'-deoxythymidine (BW A509U), which, as a triphosphate, inhibits the reverse transcriptase of HTLV-III/LAV. This agent blocks the expression of the p24 gag protein of HTLV-III/LAV in H9 cells following exposure to virus. The drug also inhibits the cytopathic effect of HTLV-IIIB (a virus derived from a pool of American patients) and HTLV-III/RF-II (an isolate obtained from a Haitian patient that differs by about 20% in the amino acid sequence of the envelope gene from several isolates of HTLV-III/LAV, including HTLV-IIIB, analyzed so far). 3'-Azido-3'-deoxythymidine also completely blocks viral replication as assessed by reverse transcriptase production in normal human peripheral blood mononuclear cells exposed to HTLV-IIIB. Finally, at concentrations of 3'-azido-3'-deoxythymidine that block the in vitro infectivity and cytopathic effect of HTLV-IIIB, the in vitro immune functions of normal T cells remain basically intact.read more
Citations
More filters
Journal ArticleDOI
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.
Margaret A. Fischl,Douglas D. Richman,M. H. Grieco,M. S. Gottlieb,Paul A. Volberding,Oscar L. Laskin,John M. Leedom,Jerome E. Groopman,Donna Mildvan,Robert T. Schooley +9 more
TL;DR: It is demonstrated that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
Journal ArticleDOI
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Rudi Pauwels,Jan Balzarini,Masanori Baba,Robert Snoeck,Dominique Schols,Piet Herdewijn,Jan Desmyter,Erik De Clercq +7 more
TL;DR: A rapid, sensitive and automated assay procedure was developed for the in vitro evaluation of anti-HIV agents, which significantly reduced labor time as compared to the trypan blue exclusion method, and permits the evaluation of large numbers of compounds for their anti-hIV activity.
Journal ArticleDOI
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Jerome A. Zack,Salvatore J. Arrigo,Stacy R. Weitsman,Alan S. Go,Allyson M. Haislip,Irvin S. Y. Chen +5 more
TL;DR: A modification of the polymerase chain reaction method is used to demonstrate that HIV-1 DNA synthesis is initiated in infected quiescent T cells at levels comparable with those of activated T cells.
Journal ArticleDOI
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection: A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter
Paul A. Volberding,Stephen W. Lagakos,Matthew A. Koch,David K. Booth,Carla Pettinelli,Maureen Myers,Henry H. Balfour,Richard C. Reichman,John Bartlett,Martin S. Hirsch,Robert L. Murphy,W. David Hardy,Ruy Soeiro,Margaret A. Fischl,John G. Bartlett,Thomas C. Merigan,Newton E. Hyslop,Douglas D. Richman,Fred T. Valentine,Lawrence Corey +19 more
TL;DR: Zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter and additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
Journal ArticleDOI
Structure-based strategies for drug design and discovery.
TL;DR: The combination of molecular structure determination and computation is emerging as an important tool for drug development and will be applied to acquired immunodeficiency syndrome (AIDS) and bacterial drug resistance.
References
More filters
Journal ArticleDOI
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
Françoise Barré-Sinoussi,J. C. Chermann,Félix A. Rey,Marie-Thérèse Nugeyre,S. Chamaret,Jacqueline Gruest,Charles Dauguet,Claudine Axler-Blin,F. Vézinet-Brun,Christine Rouzioux,Willy Rozenbaum,Luc Montagnier +11 more
TL;DR: From these studies it is concluded that this virus as well as the previous HTLV isolates belong to a general family of T-lymphotropic retroviruses that are horizontally transmitted in humans and may be involved in several pathological syndromes, including AIDS.
Journal ArticleDOI
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
Robert C. Gallo,Syed Zaki Salahuddin,Mikulas Popovic,Gene M. Shearer,Mark H. Kaplan,Barton F. Haynes,Thomas J. Palker,Robert R. Redfield,James M. Oleske,Bijan Safai,Gilbert C. White,Paul Foster,Phillip D. Markham +12 more
TL;DR: Peripheral blood lymphocytes from patients with the acquired immunodeficiency syndrome (AIDS) or with signs or symptoms that frequently precede AIDS (pre-AIDS) were grown in vitro with added T-cell growth factor and assayed for the expression and release of human T-lymphotropic retroviruses (HTLV).
Journal ArticleDOI
Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS
TL;DR: A cell system was developed for the reproducible detection of human T-lymphotropic retroviruses (HTLV family) from patients with the acquired immunodeficiency syndrome (AIDS) or with signs or symptoms that frequently precede AIDS (pre-AIDS), and it provides large amounts of virus for detailed molecular and immunological analyses.
Journal ArticleDOI
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.
Michael S. Gottlieb,Robert W. Schroff,Howard M. Schanker,J.D. Weisman,P.T. Fan,Robert A. Wolf,Andrew Saxon +6 more
TL;DR: Analysis of peripheral-blood T-cell subpopulations suggested that cytomegalovirus infection was an important factor in the pathogenesis of the immunodeficient state.
Journal ArticleDOI
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.
Henry Masur,Mary Ann Michelis,Jeffrey B. Greene,Ida M. Onorato,Robert A. Vande Stouwe,Robert S. Holzman,Gary P. Wormser,Lee R. Brettman,Michael Lange,Henry W. Murray,Susanna Cunningham-Rundles +10 more
TL;DR: Eleven cases of community-acquired Pneumocystis carinii pneumonia occurred between 1979 and 1981 and prompted clinical and immunologic evaluation of the patients, indicating that these groups may be at high risk for this infection.
Related Papers (5)
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
Hiroaki Mitsuya,Samuel Broder +1 more